[go: up one dir, main page]

MX2022000598A - Preparacion de compuestos antibacterianos. - Google Patents

Preparacion de compuestos antibacterianos.

Info

Publication number
MX2022000598A
MX2022000598A MX2022000598A MX2022000598A MX2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A
Authority
MX
Mexico
Prior art keywords
ridinilazole
preparation
processes
antibacterial compounds
bibenzo
Prior art date
Application number
MX2022000598A
Other languages
English (en)
Inventor
Francis Xavier Wilson
Jean-Francois Carniaux
Nigel Adams
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910250.8A external-priority patent/GB201910250D0/en
Priority claimed from GBGB1912144.1A external-priority patent/GB201912144D0/en
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2022000598A publication Critical patent/MX2022000598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los procesos para la preparación de 2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]imidazol (que además se puede conocer como 5,5'bis-[2-(4-piridinil)-1H-bencimidazol]), al que se hace referencia en la presente descripción con el nombre INN ridinilazol y derivados, sales, hidratos, solvatos, complejos, bioisósteros, metabolitos o profármacos farmacéuticamente aceptables de este. La invención se refiere además a diversas composiciones de ridinilazol purificado, a diversas formas cristalinas de ridinilazol, a procesos para su preparación y a preparaciones farmacéuticas relacionadas y usos de estas (que incluyen su uso médico y su uso en la síntesis efectiva a gran escala de ridinilazol).
MX2022000598A 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos. MX2022000598A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910250.8A GB201910250D0 (en) 2019-07-17 2019-07-17 Preparation of antibacterial compounds
GBGB1912144.1A GB201912144D0 (en) 2019-08-23 2019-08-23 Antibacterial compounds
PCT/GB2020/051710 WO2021009514A1 (en) 2019-07-17 2020-07-16 Process for the preparation of ridinilazole and crystalline forms thereof

Publications (1)

Publication Number Publication Date
MX2022000598A true MX2022000598A (es) 2022-03-04

Family

ID=72148169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000598A MX2022000598A (es) 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos.

Country Status (12)

Country Link
US (1) US20220289705A1 (es)
EP (1) EP3999502A1 (es)
JP (2) JP7730803B2 (es)
KR (1) KR102737283B1 (es)
CN (1) CN114127056A (es)
AU (1) AU2020315188B2 (es)
BR (1) BR112022000484A2 (es)
CA (1) CA3146788C (es)
IL (1) IL289453B1 (es)
MX (1) MX2022000598A (es)
WO (1) WO2021009514A1 (es)
ZA (1) ZA202200660B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
EP4058151B1 (en) 2019-11-13 2025-05-21 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
JP7788550B2 (ja) * 2021-10-26 2025-12-18 大鵬薬品工業株式会社 ターフェニル化合物の安息香酸塩の製造方法
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016042A1 (de) 1994-11-17 1996-05-30 F. Hoffmann-La Roche Ag Antibakterielle dibenzimidazol-derivate
EP1341769B1 (en) 2000-12-15 2007-10-17 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US7727992B2 (en) 2002-06-13 2010-06-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
CA2617123C (en) 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
HRP20160397T1 (hr) * 2010-06-01 2016-08-12 Summit Therapeutics Plc Spojevi za liječenje clostridium difficile povezanih bolesti
WO2011151618A2 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
BR112016024521A2 (pt) * 2014-04-22 2017-08-15 Arqule Inc sais e polimorfos de um composto imidazopiridinil-aminopiridina
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts

Also Published As

Publication number Publication date
BR112022000484A2 (pt) 2022-03-08
CA3146788C (en) 2024-06-18
AU2020315188A1 (en) 2022-02-10
JP2022542822A (ja) 2022-10-07
EP3999502A1 (en) 2022-05-25
JP7730803B2 (ja) 2025-08-28
CN114127056A (zh) 2022-03-01
AU2020315188B2 (en) 2025-09-18
IL289453A (en) 2022-02-01
US20220289705A1 (en) 2022-09-15
KR102737283B1 (ko) 2024-12-03
CA3146788A1 (en) 2021-01-21
ZA202200660B (en) 2024-06-26
WO2021009514A1 (en) 2021-01-21
IL289453B1 (en) 2025-11-01
KR20220024617A (ko) 2022-03-03
JP2025106244A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
MX2022000598A (es) Preparacion de compuestos antibacterianos.
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
BR112022012641A2 (pt) Compostos tricíclicos substituídos
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
NI202000078A (es) Compuestos heteroaril tetracíclicos
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX383804B (es) Derivados de piperidina.
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MY207696A (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
BRPI0417268B8 (pt) compostos benzimidazóis que contêm morfolinila, seu uso como inibidores da replicação de vírus sinciciais respiratórios, composição que os compreende e processo para preparar os referidos compostos
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MX2020003993A (es) Derivados de bencimidazol y sus usos.
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
BR112021011325A2 (pt) Derivados de rapamicina
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.